このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Standard Chemical & Pharmaceutical マネジメント

マネジメント基準チェック /04

Standard Chemical & Pharmaceutical'sの CEO はTzu-Ting Fanで、 Jul2008年に任命され、の在任期間は 15.92年です。は、会社の株式の6.58%を直接所有しており、その価値はNT$ 835.43M 。経営陣と取締役会の平均在任期間はそれぞれ1.3年と1.9年です。

主要情報

Tzu-Ting Fan

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	15.9yrs
CEOの所有権	6.6%
経営陣の平均在職期間	1.3yrs
取締役会の平均在任期間	1.9yrs

経営陣の近況

Recent updates

If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late

Apr 13

Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Jan 19

Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today

Jan 04

Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?

Dec 22

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Dec 08

Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly

Nov 26

CEO（最高経営責任者

Tzu-Ting Fan

15.9yrs

在職期間

Mr. Tzu-Ting Fan serves as General Manager and Director of Standard Chem. & Pharm. Co., Ltd.and its President since July 1, 2008. He serves as Representative of Corporate Director of Syn-Tech Chem. & Phar...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Tzu-Ting Fan	President	15.9yrs	データなし	6.58% NT$ 873.1m
Chin Wen Chang	Financial Officer	1.3yrs	データなし	データなし
Chin-Tsai Fan	GM & Director	1.3yrs	データなし	データなし

1.3yrs

平均在職期間

経験豊富な経営陣: 1720の経営陣は経験豊富とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Tzu-Ting Fan	President	no data	データなし	6.58% NT$ 873.1m
Chin-Tsai Fan	GM & Director	no data	データなし	データなし
Yuan-Teh Lee	Director	no data	データなし	データなし
Wen-Chang Lin	Additional Director	less than a year	データなし	0.052% NT$ 6.9m
Hwei-Jiung Wang	Independent Director	no data	データなし	データなし
Lin-Yu Lee	Independent Director	no data	データなし	0.017% NT$ 2.2m
Tsuey-Wen Yeh	Director	3.4yrs	データなし	データなし
Shaw-Tzong Liu	Independent Director	2.8yrs	データなし	データなし
Lawrence C. Lee	Additional Independent Director	less than a year	データなし	データなし

1.9yrs

平均在職期間

経験豊富なボード: 1720の取締役会は経験豊富ではない ( 1.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Standard Chemical & Pharmaceutical マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Standard Chemical & Pharmaceutical Co. Ltd., Annual General Meeting, Jun 20, 2024

Standard Chemical & Pharmaceutical Co. Ltd. Elects One Additional Director and One Additional Independent Director

Less than half of directors are independent

Less than half of directors are independent

Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 21, 2022

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: NT$1.41 (vs NT$1.18 in 1Q 2023)

Standard Chemical & Pharmaceutical Co. Ltd. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings released: EPS: NT$4.67 (vs NT$4.56 in FY 2022)

Standard Chemical & Pharmaceutical Co. Ltd., Annual General Meeting, Jun 20, 2024

Now 20% overvalued after recent price rise

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Third quarter 2023 earnings released: EPS: NT$1.25 (vs NT$1.34 in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$1.33 (vs NT$1.28 in 2Q 2022)

Upcoming dividend of NT$2.50 per share at 3.8% yield

Standard Chemical & Pharmaceutical Co. Ltd. Elects One Additional Director and One Additional Independent Director

Investor sentiment improves as stock rises 22%

Full year 2022 earnings released: EPS: NT$4.56 (vs NT$3.96 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$1.34 (vs NT$0.89 in 3Q 2021)

Now 20% undervalued

Now 20% undervalued

Second quarter 2022 earnings released: EPS: NT$1.28 (vs NT$0.93 in 2Q 2021)

Upcoming dividend of NT$2.50 per share

First quarter 2022 earnings released: EPS: NT$0.97 (vs NT$1.17 in 1Q 2021)

Less than half of directors are independent

Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS NT$0.89 (vs NT$0.64 in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.73 in 2Q 2020)

Upcoming dividend of NT$1.80 per share

First quarter 2021 earnings released: EPS NT$1.17 (vs NT$0.67 in 1Q 2020)

If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late

SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million.

Full year 2020 earnings released: EPS NT$2.93 (vs NT$2.11 in FY 2019)

Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 18, 2021

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Does Standard Chem & Pharm (TPE:1720) Have A Healthy Balance Sheet?

Should Standard Chem & Pharm (TPE:1720) Be Disappointed With Their 11% Profit?

Is Standard Chem & Pharm CO., LTD.'s (TPE:1720) 4.3% Dividend Worth Your Time?

New 90-day low: NT$35.20

Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

New 90-day low: NT$36.50

Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today

Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly

Third quarter 2020 earnings released: EPS NT$0.64

New 90-day low: NT$37.55

New 90-day low: NT$37.70

New 90-day low - NT$38.30

First half earnings released

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

マネジメント基準チェック /04